METASTATIC CANCER

This study tested whether adding a third drug (ipilimumab) to a standard two-drug combination (atezolizumab and bevacizumab) works better for people with advanced liver cancer that cannot be treated with surgery. It involved 229 patients who received either the two-drug or three-…

This study tested an experimental drug called ozuriftamab vedotin (BA3021) in people with advanced head and neck cancer that had returned or spread. The main goals were to see if the drug could shrink tumors and how safe it was. It included 42 adults whose cancer was not curable …

This study tested whether adding targeted, high-dose radiation to immunotherapy helps control advanced cancer better than immunotherapy alone. It involved 106 patients with metastatic cancer that had spread throughout their bodies. Researchers compared two groups: one received im…

This early-stage study tested the safety and optimal dosing of an experimental oral medication called Q702 in patients with advanced solid tumors. The trial involved 51 adults whose cancers had progressed despite standard treatments or who had no effective standard options availa…

This early-stage study aimed to find safe doses for several different combinations of cancer drugs in patients with advanced or metastatic solid tumors, including lung cancer. The 60 participants were divided into groups to test combinations of chemotherapy, immunotherapy, and ta…

This early-stage study tested the safety of a new two-part treatment for advanced cancers that have spread. The treatment combines a specially engineered virus designed to attack tumors with an existing immunotherapy drug. It involved 14 patients whose cancer had progressed despi…

This early-stage study tested whether adding a new investigational therapy called VE800—a preparation of specific bacteria—could improve the effectiveness of an existing immunotherapy drug (nivolumab) in patients with advanced or metastatic cancers. The trial enrolled 56 patients…

This first-in-human study tested a new oral medication called MRX-2843 in adults with advanced solid tumors that had returned or stopped responding to standard treatments. The main goals were to find the highest safe dose and understand how the drug moves through the body. Resear…

This early-stage study tested a new oral drug called ART4215 in people with advanced or metastatic solid tumors, including breast cancer. The main goals were to find a safe dose for the drug when taken alone and when combined with other cancer drugs, and to check for early signs …

This study tested whether a precise, high-dose radiation technique called SABR is safe for people whose cancer has spread to more than 10 places in the body. It involved 13 patients with advanced metastatic cancer who had run out of standard treatment options. The main goal was t…

This study tested if adding two older leukemia drugs (6MP and 6TG) to a modern immunotherapy drug (atezolizumab) could help control advanced solid tumors. The idea was that the older drugs might cause more mutations in the cancer, making it more visible to the immune system. It i…

This study looked at how two newer, targeted breast cancer drugs performed in everyday medical practice, not just in controlled trials. It followed 312 patients with advanced breast cancer who had already tried other treatments. The main goal was to understand the real-world safe…

This first-in-human study tested a new experimental drug called HMBD-002, which targets a protein on cancer cells called VISTA. The trial aimed to find a safe dose and schedule for giving HMBD-002 alone and combined with the approved immunotherapy drug pembrolizumab (Keytruda®) i…

This study tested whether a brief, 6-minute motivational interview in the emergency department could help seriously ill older adults start planning their future medical care. Researchers enrolled 141 adults aged 50+ with conditions like heart failure or cancer to see if the short…

This study tested whether giving a booklet with example questions to patients with advanced cancer or their families before a palliative care meeting would change what they ask their doctors. Researchers wanted to see if the booklet helped people get more or different information…